A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

Weight loss injections are popular among adults, but a new study suggest they could be useful in fighting childhood obesity, ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Deutsche Bank downgrades AstraZeneca (AZN) and Roche (RHHBY) after disappointing data for thier key pipeline assets. Read ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Overall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having ... and no unexpected efficacy loss." Though Roche's statement is carefully couched to imply that getting ...